PROJECT REPORT ON Production Planning, Distribution and Logistics SUBMITTED IN PARTIAL FULFILLMENT OF Degree of Master of Business Administration Submitted by: Narendra Prakash Under Supervision of Amrendra P Singh DGM- Distribution & Logistics Cadila Pharmaceutical Ltd. Department of Management Studies JAMIA HAMDARD
61
Embed
Production Planning,Distribution and Logistics-pharma
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
PROJECT REPORT ONProduction Planning, Distribution and
Logistics
SUBMITTED IN PARTIAL FULFILLMENT OF
Degree of
Master of Business Administration
Submitted by:Narendra Prakash
Under Supervision ofAmrendra P Singh
DGM- Distribution & LogisticsCadila Pharmaceutical Ltd.
Department of Management StudiesJAMIA HAMDARD
NEW DELHI
ACKNOWLEDGEMENT
Every mature individual in professional life is keenly aware of his sense of indebtness to many
people who have stimulated and influenced his intellectual development. Ordinarily, this feeling
is expressed in customercy gesture of acknowledgement. Therefore it seems as a right to
acknowledge my gratitude with sense of veneration to Almighty God.
I am grate full to Mr. Sanjeev Kumar Director of Akums pharmaceuticals Ltd. for his
innovative guidance and blessings and providing all facilities related to my project work.
It is delightful moment for me to put into all my gratitude to my esteemed guide Mr. Shahbaz
Alam Product Manager of Plenteous Pharmaceuticals Ltd. for his valuable suggestion and
constant encouragement.
I am also thankful to Dr. Vivek Srivastav Manager Product Development of Akums
Pharmaceuticals Ltd. for their support and Miss Kopal Gupta Product Executive of
Plenteous Pharmaceuticals Ltd.
I am also thankful to Department of Management Studies for nurturing & shaping my skills to
meet the complexities of my project.
I acknowledge my profound thanks to my friends and my family who encourage me to complete
Last year, India imported pharmaceutical products worth Rs 1500 crore from various countries,
according to official figures.
However, it is not still a practice for India to visit the manufacturing facilities to conduct
inspections to ascertain the qulaity of medicines being sourced by Indian companies.
Most of the countries importing pharmaceutical products made in India send their personnel to
visit Indian manufacturing facilities to verify and authenticate the manufacturing standards to
ensure quality of the products before giving okay for importing.
“Inspectors from other countries, from Nepal to the US, come to India to check manufacturing
facilities of Indian drug companies.
India also get drugs imported from many countries such as Taiwan and China for which we will
start sending our inspectors to examine whether they are following good manufacturing
practices,” stated Dr Surinder Singh, Drug Controller General of India (DCGI) who heads
India’s apex drug regulatory body.
India will also soon start this practice close in line with the other countries, said Dr Singh. But he
did not reveal much on the nature and time of such overseas inpections.
Currently, India has nearly 100 pharmaceutical manufacturing facilities approved the US Food
and Drug Adiministration. This is the largest number of facilities outside the US, approved to
source pharmaceuticals by USFDA -which sets one of the world’s most stringent quality
parameters. USFDA conducts inspections periodically before giving approval for each
pharmaceutical product to ensure that it follows the good manufacturing practice (GMP)
standards set by the federal regulator.
If caught for any lapses, even minor, including the errors in documentations, USFDA instantly
go for immediate action.
Show cause notices have been sent out by the US FDA for several of Indian manufacturing
facilities including that of Ranbaxy, Wockhardt, Sun, Lupin Cipla etc over the years, after
finding manufacturing errors during inspection in their USFDA approved facilities.
Most recently, US FDA even went to the extend of suspending the certification of Ranbaxy’s
formulations manufacturing facility Paonta Sahib for not following set procedures. This followed
a ban in importing products manufactured in Paonta Sahib, inflicting huge losses to Ranbaxy.
Ranbaxy, now a subsidiary of Daiichi-Sankyo of Japan is one of India’s leading drug exporters
to US.
Similarly, US FDA has also issued notices to Cipla, another big time export of pharmaceutical
products from India.
Manufacturing facilities of Indian drug makers are also inspected and audited by MHRA of UK,
ANVISA of Brazil, MCC of South Africa, TGA of Australia etc.
Therefore, it’s hightime India too started the practice of inspecting to bring in more transparency
into the drug approval system, the DCGI said.
The pharmaceutical exports from India for the first nine months of the fiscal 2008-09 have
peaked upto $1.2 billion, despite a slowdown in overseas trade across all industries owing to
recessional fears.
Total exports in pharmaceutical products from India in December 2008 surged by 46.3 per cent
to 1.01 billion dollars from 609 million dollars in the same month of the previous fiscal,
according to Pharmaceuticals Exports Promotion Council (PHARMEXCIL) - separate governing
body to oversee pharma exports under the Ministry of Commerce & Industry.
The overseas sales in the first nine months of 2008-09 went up by 21 per cent to 8.44 billion
dollars against 6.97 billion dollars in 2007-08.
Despite this, India’s pharma exports to US is severely hit in recent months by increasing
competition from other emerging markets like China, Israel and Korea, said a study conducted
by Federation of Indian Chambers of Commerce and Industry –an umbrella association
representing Indian businesses.
Pharmaceutical export business remains the worst hit among all the industries due to the
economic down turn in US. Indian exports of pharmaceutical products to the US fell almost 40
per cent in the five months between October last year and the end of February.
Exports of pharmaceutical products from India have been facing steady competition in the US
market from its Asian peers such as China and South Korea as well from Israel. In fact Indian
pharma companies are increasingly losing their relative share to firms from these emerging
economies.
The pharmaceutical exports from India for the first nine months of the fiscal 2008-09 have
peaked upto $1.2 billion, despite a slowdown in overseas trade across all industries owing to
recessional fears
4. RESEARCH METHODOLOGY
4.1 OBJECTIVE OF STUDY
Finding out the actual demand of Nutraceuticals in Delhi
To know the trends of Nutaceuticals in Indian market.
To know the individual preference of physicion, dietician, slimming
centers,& gym.
To know the different idea & demand for the product
To know the utilization of product of Nutraceuticals.
4.2 DURATION OF STUDY
45 Days from 1st of june to 15th of july
4.3 AREA OF STUDY
1. TRADE
i. Ashram
ii. Sarita Vihar
iii. Sukhdev Vihar
iv. Junkpura
v. Nizamuddin
vi. New Friends Colony
2. HOSPITAL:
i. Escort
ii. Apollo
iii. Sujan Mahindra
iv. Holy Family
4.4 RESEARCH DESIGN
The purpose of the study was to explore the market of the nuteceutical. For this
individuals were segmented based on doctors, slimming center and gym. To target this
position perception and future prospect of the drug, a survey was conducted through
which an analysis was drawn.
Sampling technique
The random sampling technique was used for the survey.
Questionnaire filled by physician, dietician, slimming center and gym
Time duration was 45 days for data collection.
Data collection
Data would be collected through primary and secondary sources
i. Primary source of data collection is through questionnaire.
ii. Source of secondary data is published reports, magazines & internet.
5. ANALYSIS OF STUDY
PHYSICIAN RESPONSE
DIETICIAN RESPONSE
OTHERS(SLIMMING CENTER &GYM) RESPONSE
6. CONCLUSION
After analyzing the data, it is concluded that there is great oppurtinity of Nutraceutical in Indian
market. There is a huge demand of these products in slimming center and gym.
There is lack of proper awareness among doctors about Nutraceutical and their products.
Nutraceuticals are destined to play an important role in future therapeutic developments but their
success will be governed by control of purity, safety and efficacy without inhibiting innovation.
Nutraceuticals will continue to appeal because they are convenient for today’s lifestyle. The
present accumulated knowledge about nutraceuticals represents undoubtedly a great challenge
for nutritionists, physicians, food technologists and food chemists. Public health authorities
consider prevention and treatment with nutraceuticals as a powerful instrument in maintaining
health and to act against nutritionally induced acute and chronic diseases, thereby promoting
optimal health, longevity and quality of life. A place for Nutraceuticals in clinical practice is
emerging.
The US alone accounted for 37 percent of 2007 Nutraceutical sales, but Asia Pacific is expected
to emerge as the fastest growing market, boosted by the "robust" Chinese and Indian markets,
and increasing economic prosperity, said the report
7. RECOMMENDATIONS
Indian Nutraceutical markets are in small stage. India can become a big player in this industry if
it develops clinical documentation and scientific basis to support claims of safety and efficacy.
following recommendations/suggestions are:
1. by developing awareness among Indian populations.
2. by creating awareness among physician about Nutraeutical and its product.
3. by scientific advertisement and promotion
4. To grow this segment of market, the company should initially focus on the slimming
center and gym
5. For winning doctors attitude, the company should make strategies for the TOP OF THE
MIND RECALL for the brand with different strategies which include brand building
through proper communication and advertisement.
6. Marketing department should be tight enough to generate awareness about plenteous and
its products.
7. Proper advertisement is one of the most important thing company should take care of
objectively.
This will become even more important if India wants to become a major player.
Areas of concern
The lack of quality control is a major area of concern for nutraceuticals. The quality of plant
material and manufacturing processes used for nutraceuticals are regulated by food laws, which
lack the specificity required for botanical drugs. This can have serious consequences.
Contamination, for instance, with toxins after fungal infection of raw plant material or with other
ingredients has been repeatedly reported and can have potential fatal consequences.
Adulterations and numerous other types of impurity of nutraceuticals conceivably remain
undetected simply because there is an almost total absence of specific quality control. Absence
of quality control not only increases the risk to the consumer, it also results in a total lack of
impetus to conduct adequate research that demonstrates the potential benefits of nutraceuticals or
ensures their safety. New clinical applications of nutraceuticals are increasingly being reported,
but there are fundamental differences between formulation, production and the evidence
supporting clinical use. Nutraceuticals generally fall within the novel foods and ingredients
regulations but their purity, dosage requirements and clinical consequences exceed those of most
‘healthfoods’. Replacement of one nutrient or antioxidant is unlikely to correct the cascade of
interconnected metabolic abnormalities associated with many diseases. Cost is another factor that
receives scant attention. These products sell for substantial amounts more than mainstream
products, in as much as botanicals are costly to produce
8.ANNEXURE
Nutraceutical Market Survey
Questionnaire
Q.1 Out of these following lifestyle diseases which is the most prevailing in India. Mention 1,2,3,4 on priority basis.
Obesity Diabetes
Hypertension Constipation
Q.2 What are the common ailments in nuclear family of metro city? Mention 1, 2,3,4,5 on priority basis.
Constipation Sleeplessness Depression
Morning Fatigue Body ache
Q.3 Why Indian Nutraceuticals market size is just 0.036 %(Rs. 2700 cr.)of global Nutraceutical Market(7,50,000 Cr.)? Mention 1, 2, and 3 on priority basis from the following options
Untapped Market Lack of awareness
Promoted unscientifically
Q.4. Obesity has become globesity and it stops us from doing our day to day performance and apart from this we suffer with other manifestation of diseases. BBT-SLIM Caps reduces body weight 1-3 kg in a month. It reduces LDL & TG (Bad Cholesterol) by 17%. Moreover it increases HDL (Good Cholesterol) by 37%, which no other product offers. Are you interested to take 15 days course free of cost?
Yes No
Q.5. Those who are obese, remain loaded with lot of diseases especially Hypertension, Diabetes
and Hypercholestereamia.DH2 Caps is a wonderful product recommended for overweight people
associated with diabetes and hypertension (age35+). Are you interested to take 15 days course
free of cost?
Yes No
Q.6 STF-FRESH Caps as the name indicates is the blend of precious valuable nutraceuticals.
Metro life is full of tension and people hardly get time to spare for lifrstyle management that
leads to lots of lifestyle diseses such as sleeplessness, morning fatigue,depression constipation,
body ache.STF-FRESH offers you not only sound sleep,energy, mood elevation but also gives
you freedom from constipation, morning fatigue and body ache. Are you interested to take 15